Inspan Releases Product Brochures To Patients And Doctors
Static testing in a load to failure mode for disassembly
The Inspan technique is a safe new treatment paradigm for patients suffering from degenerative disc disease, spinal stenosis and facet arthropathy. Inspan’s unique interlaminar design allows for decompression and distraction of the spinal canal and foramen while stabilizing the facet joints. Inspan offers a wide array of implant sizes ranging from 8mm to 20mm. Inspan has been FDA-cleared since 2010 and its efficacy has been supported by clinical studies and biomechanical data to be the strongest fixation with no reported device related failures.
Indications For Use:
The Inspan ScrewLES Fusion System is a posterior non-pedicle supplemental fixation system intended for use in the non-cervical spine (T1-S1). It is intended for plate fixation/attachment to the spinous process for the purpose of achieving supplemental fusion for the following indications: spondylolisthesis, trauma (fracture or dislocation), tumor, degenerative disc disease (defined as discogenic pain with degeneration of the disc confirmed by history and radiographic studies) or lumbar spinal stenosis. The device is intended for use with bone graft material and is not intended for stand-alone use.
About INSPAN, LLC
INSPAN, LLC is privately owned by the KICVentures Group and is focused on advancing the platform of patented interspinous interlaminar fixation technology. The Inspan device has a proven ten-year track record with thousands implanted since FDA clearance in 2010. There are no documented device-related failures or spinous process fractures that have plagued other competitive ISP devices.
https://myinspan.com/
About KICVentures Group
Our founders have been investing in spine surgery since 2000, which makes us the most experienced healthcare investment holding company with the largest portfolio of medical device technologies focused on solutions for less invasive outpatient spine surgery. Our investment strategy is to acquire or invent disruptive technologies using our own capital or partner with private individual investors. This allows us the freedom to make quick and nimble long-term decisions with leading physicians to advance clinical outcomes, such as when we acquired AxioMed Viscoelastic Disc Technologies, while the leading spine companies look the other way to invest in advancing spinal fusion.
https://www.kicventuresgroup.com/
Authors
Dr. Kingsley R. Chin MBA is a board-certified Professor of Orthopedic Spine Surgery and honors graduate of Harvard Medical School and the Harvard Combined Orthopedic Residency Program. He did his spine fellowship with Dr. Henry H Bohlman. He was Chief of Spine Surgery at the University of Pennsylvania.
Dr. Jason A. Seale is a medical doctor and entrepreneur. He is the clinical director at the LES Clinic. He holds a Masters in Business Administration degree